KRAS and non-small cell lung carcinoma: However, our study broadens this knowledge by analyzing two EGFR‐mutant cell lines, unlike most RKIP studies in lung cancer, which focus on KRAS‐mutant A549 cells [31, 32], thus expanding the understanding of RKIP's relevance in EGFR‐mutant settings, which account for 10–30% of NSCLC cases [9].